Array Biopharma Inc., of Boulder, Colo., and Pierre Fabre SA, of Castres, France, reported results from the pivotal phase III COLUMBUS trial of binimetinib plus encorafenib (bini/enco) treatment in BRAF-mutant melanoma patients at the Society for Melanoma Research meeting in Boston.